On December 5 - 9, 2016 at “Expocenter” Central Exhibition Complex, as part of the Russian healthcare week, “PharmMedProm 2016” exhibition tool place aimed at demonstrating the results of the implementation of the national program “Development of pharmaceutical and medical industry for 2013-2020”. Ministry of Industry and Trade of the Russian Federation was the organiser of the exhibition.
On an opening day, the Enterprise’s roll-up was attended by the guests of the exhibition display - the First Deputy Minister of Healthcare of the Russian Federation, I. N. Kagramanyan, the Deputy Minister of Healthcare of the Russian Federation, S.A. Kraevoi, the Deputy Minister of Industry and Trade of the Russian Federation, S.A. Tsyb, and the Director of the Department for Development of Pharmaceutical and Medical Industry, O. N. Kolotylova.
FSUE Moscow Endocrine Plant is an active participant of the Federal dedicated programme “Development of pharmaceutical and medical industry of the Russian Federation for the period up to 2020 and beyond”. The Enterprise took part in a collective exposition of the Ministry of Industry and Trade of Russia, by presenting new medicinal products introduced in 2016, “MIDAZOLAM, solution for intravenous and intramuscular administration”, “TROPICAMIDE eye drops”, “CLONAZEPAM tablets”, and “Levofloxacin”, eye drops.
“MIDAZOLAM, solution for intravenous and intramuscular administration” was registered in 2016 as part of the Federal target program “Development of pharmaceutical and medical industry of the Russian Federation for the period up to 2020 and beyond”. The product is widely used in anaesthesia for premedication prior to anaesthetic induction as a sedative component in combined anaesthesia, for sedation with the preservation of consciousness before diagnostic and treatment procedures performed under local anesthetization or without, and during the process itself. It is a socially significant medicinal product and the first generic produced in Russia.
“Levofloxacin eye drops” is an in-house design of FSUE Moscow Endocrine Plant, the marketing authorization was obtained in 2016. The product has a wide spectrum of antimicrobial effect and is intended for treatment of eye bacterial infections.
Comment type is not specified in the component properties.